ストックスクリーナーアプリを入手
30.50
2.83%
0.84
Amphastar Pharmaceuticals Inc (AMPH) 最新ニュース
Connor Clark & Lunn Investment Management Ltd. Reduces Stock Position in Amphastar Pharmaceuticals, Inc. $AMPH - MarketBeat
Amphastar Pharmaceuticals Enters Strategic Licensing Agreement - MSN
Published on: 2025-08-18 07:29:06 - sundaytimes.kr
Amphastar raised to Buy at Needham on iron sucrose injection approval - MSN
Amphastar Pharmaceuticals (NASDAQ:AMPH) Upgraded to Buy at Needham & Company LLC - MarketBeat
Is It Too Late to Sell Amphastar Pharmaceuticals Inc.Weekly Profit Analysis & AI Enhanced Execution Alerts - sundaytimes.kr
Drawdown in Amphastar Pharmaceuticals Inc. May Be Nearing EndJuly 2025 Snapshot & Real-Time Stock Entry Alerts - newsimpact.co.kr
Dextrose Injection Market Size, Share, Emerging Demands, - openPR.com
Amphastar boosts pipeline with exclusive licensing deal from Nanjing Anji - MSN
How does Amphastar Pharmaceuticals Inc. perform in inflationary periods2025 Technical Overview & AI Powered Buy and Sell Recommendations - thegnnews.com
5 Insightful Analyst Questions From Amphastar Pharmaceuticals’s Q2 Earnings Call - TradingView
Amphastar Pharmaceuticals (NASDAQ:AMPH) Shares Up 12.1%Still a Buy? - MarketBeat
Amphastar and Anji make licence agreement for three new peptides - Yahoo Finance
Amphastar Pharmaceuticals Q2 Earnings Call Highlights: Strong BAQSIMI Sales, Manufacturing Expansion, and Regulatory Progress, but Revenue Decline and Competition Challenges. - AInvest
Amphastar Pharmaceuticals’ Mixed Earnings Call Highlights - TipRanks
Amphastar Pharmaceuticals Gets Upgrade to Buy at Needham on AMP-002 Approval - AInvest
Amphastar Pharmaceuticals Upgraded to Buy by Needham Analyst - AInvest
Amphastar Pharmaceuticals, QuidelOrtho, Integra LifeSciences, Select Medical, and Regeneron Stocks Trade Up, What You Need To Know - Yahoo Finance
Amphastar Pharmaceuticals Secures FDA Approval for Iron Sucrose Injection, Sets Sights on Major Sales Momentum - AInvest
Amphastar Secures FDA Nod For Iron Sucrose Injection, Analysts Eye Major Sales Momentum - Benzinga
Amphastar Soars 11% on Intraday Surge: What’s Fueling the Momentum? - AInvest
Amphastar Pharmaceuticals upgraded to Buy by Needham after FDA approval for iron sucrose injection. - AInvest
Amphastar stock gains after licensing deal for three peptide therapies By Investing.com - Investing.com Canada
Amphastar Pharmaceuticals: Strategic Positioning and Robust Pipeline Justify Buy Rating - TipRanks
Needham upgrades Amphastar Pharmaceuticals stock to Buy on iron sucrose approval - Investing.com Canada
Iron Sucrose Competition Expands With Viatris and Amphastar FDA Approvals - insights.citeline.com
Amphastar licenses three peptide therapies in oncology, ophthalmology deal By Investing.com - Investing.com South Africa
Amphastar licenses three peptide therapies in oncology, ophthalmology deal - Investing.com
Amphastar gets FDA nod for generic iron sucrose injection - MSN
Amphastar Shares Rise Following FDA Approval of Generic Iron Sucrose Injection - MSN
Amphastar Pharmaceuticals, Inc. Bolsters Proprietary Pipeline Through Exclusive Licensing Agreement with Nanjing Anji Biotechnology Co., Ltd - MarketScreener
Amphastar Pharmaceuticals Bolsters Proprietary Pipeline Through Exclusive Licensing Agreement with Nanjing Anji Biotechnology Co., Ltd. - ACCESS Newswire
AMPH Q2 Deep Dive: BAQSIMI Momentum, Margin Pressures, and Pipeline Milestones - Yahoo Finance
Primatene Mist Sales Flat As Amphastar Plans Production Expansion To Support Pipeline - insights.citeline.com
Amphastar Pharmaceuticals Receives FDA Approval for Generic Iron Sucrose Injection - AInvest
FDA Approvals for Iron Sucrose Products by Viatris, Amphastar Pharmaceuticals - AInvest
Amphastar Pharmaceuticals (AMPH) stock surges 10.4% on FDA approval for generic Iron Sucrose Injection treatment for iron deficiency anemia. - AInvest
Why Is Amphastar Pharmaceuticals (AMPH) Stock Soaring Today - Yahoo Finance
FDA OKs Generic Iron Sucrose for CKD Anemia - Conexiant
Amphastar Soars 14.36% on FDA Approval: A Game-Changer or Fleeting Rally? - AInvest
Amphastar stock rises after FDA approves generic iron sucrose injection By Investing.com - Investing.com Canada
FDA approves Amphastar’s iron sucrose injection for anemia treatment By Investing.com - Investing.com Nigeria
FDA approves Amphastar’s iron sucrose injection for anemia treatment - Investing.com
Amphastar Announces FDA Approval for Iron Sucrose Injection, USP - ACCESS Newswire
18,358 Shares in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Purchased by XTX Topco Ltd - MarketBeat
Amphastar Pharmaceuticals (AMPH) Q2 Earnings and Revenues Beat Estimates - msn.com
Utah Medical Products Reports Q2 Decline - AOL.com
Amphastar Pharmaceuticals (NASDAQ:AMPH) Price Target Cut to $25.00 by Analysts at Piper Sandler - MarketBeat
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Q2 2025 Earnings Call Transcript - Insider Monkey
Pfizer beats in Q2 earnings, reaffirms 2025 outlook [Video] - AOL.com
Technical Models Suggest Amphastar Pharmaceuticals Inc. May Rebound Soon - beatles.ru
Interpace Biosciences Earnings Drop - AOL.com
Amphastar Pharmaceuticals Inc (AMPH) Q2 2025 Earnings Call Highlights: Strong Vaccine Sales and ... By GuruFocus - Investing.com Canada
2.37%
0.37%
大文字化:
|
ボリューム (24 時間):